Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MBPH | Stockholm | SEK | Real-time | |
MOBs | BATS Europe | SEK | Delayed |
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Lennart Emtestam | - | - | Member of Scientific Advisory Board |
Jan Faergemann | - | - | Member of Scientific Advisory Board |
Howard J. Maibach | - | - | Member of Scientific Advisory Board |
Bernt Lindelöf | - | - | Member of Scientific Advisory Board |
Johan Heilborn | - | - | Member of Scientific Advisory Board |
Kerstin Valinder Strinnholm | 64 | 2022 | Independent Chairman of the Board |
Hakan Wallin | 62 | 2023 | Independent Director |
Anders Lundmark | 66 | 2022 | Independent Director |
Nikolaj Sorensen | 52 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review